Osimertinib was the first drug to be approved for adjuvant treatment after complete tumor resection in adults with stage IB
Continue reading »
Home »
Atezolizumab prolongs survival in NSCLC with PD-L1 expression
(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in
Continue reading »
Liquid Biopsy-Based Test IDs Biomarkers in Metastatic NSCLC
FRIDAY, March 1, 2019 — A cell-free DNA (cfDNA) analysis using a 73-gene panel can successfully be used to identify
Continue reading »
ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell
Continue reading »